Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers.
Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity.
The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.
NLAB Saga® is a perfectly spherical, fully porous silica with superior mechanical stability and exceptional
chemical stability at high and low pH, making it an optimum choice for large scale purification of peptides.
Nanaologica Receives Order on NLAB Saga® Valued at approx. SEK 1,9 Million from Returning Customer in China Nanologica has received another order for the company’s silica-based purification media NLAB Saga® from a returning customer in China. This is the fourth order since June from this customer who uses NLAB Saga® in the production of a
FINANCIAL SUMMARY Net sales for the third quarter amounted to SEK 611 thousand (342) and for the nine-month period to SEK 7,822 thousand (1,368) Operating loss for the quarter amounted to SEK -22,203 thousand (-10,292) and for the nine-month period to SEK -47,365 thousand (-34,324) Loss before tax for the quarter amounted to SEK -23,701
Nanologica AB (publ) (“Nanologica” or the “Company”) today announces the outcome of the Company’s rights issue of approximately SEK 99.4 million (the “Rights Issue”), for which the subscription period ended on October 14, 2024. The Rights Issue concerns so-called units, consisting of four shares and one free of charge warrant of series TO 2024/2025 (“Unit”).
Interview with Katarina Alenäs,
SVP Chromatography
Interview with Olga Krivosheeva, Ph.D.
Application Project Manager
Interview with Chunfang Zhou, Ph.D.
Sales Manager China
Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.
For more videos presentations of the company and of interim reports, please refer to Investor Relations.
Company presentation made by CEO Andreas Bhagwani in June, 2023.
Investor Pitch Deck November 2024.
Please contact us at ir@nanologica.com for more information.
